Spinocerebellar Ataxia
New spinocerebellar ataxia research, summarized each month in plain language.
2026 so far: So far in 2026 (January to September), a randomized SCA3 trial reported that NBP improved ataxia scores versus placebo. The months covered also added evidence for stimulation and rehabilitation approaches, and for stepwise genetic testing. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- NBP for SCA3 symptoms. A 12-month randomized SCA3 medicine trial reported benefit.
- Stimulation and rehab results. Evidence shifted toward sham-controlled stimulation plus task-focused training outcomes.
- FGF14 repeat testing. Cohorts and reviews clarified yield, thresholds, and testing pitfalls.
- Tracking progression tools. More studies linked MRI and biomarkers to severity and change.
- Symptoms beyond balance. Reports broadened focus to pain, vision, mood, cognition, and autonomic symptoms.
New
September 2026
- NBP trial result. In one trial, NBP improved SCA3 ataxia scores versus placebo.
- Astragalus trial result. Astragalus showed no clear change in a nerve-injury blood marker.
- Stepwise genetic testing. Repeat-expansion tests found many adult cases; sequencing found additional ones.
- Symptom tracking tools. A questionnaire detected small one-year changes, with unclear meaning.
August 2026
- Rhythm speech cues. Rhythm cues changed speech timing, but also slowed speech rate.
- Lab drug testing. Omaveloxolone partly protected SCA3 models, not shown in people.
- Progression markers. Repeat length and one MRI measure were linked to faster worsening.
- Genetic testing gaps. Long-read tests found repeat expansions, but many still lacked a diagnosis.
July 2026
- Diagnosis clues. Non-movement symptoms sometimes guided the right genetic test.
- Spinal fluid protein. In SCA3, a disease-related protein shifted over repeat spinal taps.
- Daily vision speed. Many adults reported slower visual processing in daily activities.
- Lab-stage SCA3 therapies. Stem cells and gene editing helped models, not yet people.
June 2026
- Diagnosis changes over time. Some improved early, but later diagnoses sometimes changed.
- Scrambler therapy pain report. One SCA3 patient reported weeks of pain relief after scrambler therapy.
- SCA27B symptom pattern. A large review confirmed common walking and eye-movement problems in SCA27B.
- MRI trial measures. MRI and other brain tests matched symptoms, but were not tracked long-term.
May 2026
- FGF14 repeat testing. FGF14 repeat expansions explained a share of later-onset ataxia cases, but some standard genetic tests can miss this type of change.
- Rare causes found with broader tests. RNA-based and broader genetic testing sometimes identified uncommon causes that were not detected with earlier testing.
- SCA3 MRI tracking. In SCA3, MRI measures of the brainstem, cerebellum, and their connections tracked worsening more consistently than many other measures.
April 2026
- Stimulation with gait training. Cerebello-spinal stimulation paired with gait training improved short-term walking and balance scores more than gait training with sham stimulation.
- MRI changes before symptoms. In SCA1, cervical spinal cord MRI changes were reported before clear symptoms and continued to change over about a year.
- Nerve pathway test differences. Nerve pathway tests showed different patterns across SCA genetic types and disease stages.
- Signals seen in animal models. Animal and lab studies pointed to immune, RNA-processing, and glutamate-related signals, but these findings are not yet confirmed in people.
March 2026
- Practice helps practiced tasks. In rehab studies, people often improved most on the specific tasks they practiced, more than on overall ataxia severity ratings.
- Memory changed most in training. In a home-based cognitive training study in SCA2, memory measures improved the most, while other thinking skills changed less.
- Wearables detect early gait change. In presymptomatic SCA2, wearable sensors detected gait changes over time that may not be captured as clearly by standard clinic rating scales.
- Treatment ideas are still preclinical. Early treatment approaches reduced disease-like signals in mouse or cell models, but these results are not evidence of benefit in people.
February 2026
- Non-drug symptom approaches. In SCA3, brain stimulation changed brain-wave patterns compared with sham, and those patterns were linked to later symptom improvement, while MRI-feedback training helped some people but not the whole group.
- MRI measures for progression. In SCA1 and SCA3, several MRI measures changed over time more clearly than standard ataxia scoring, supporting MRI outcomes as tools for early-stage research.
- Genetic testing can miss SCA27B. Reports on SCA27B showed that an FGF14 repeat expansion may be missed by common genetic tests, which can leave results inconclusive until repeat-focused testing is done.
- Early biology signals. Lab studies suggested immune-cell activity in SCA1 and stress-response problems in SCA3 models, which may guide research but are not ready for routine care.
January 2026
- Home aerobic exercise. Aerobic exercise slightly improved step length versus balance training.
- Symptoms beyond balance. In SCA3, nerve symptoms tracked with worse daily function, while autonomic symptoms tracked with lower quality of life.
- Home video ratings. In SCA3, home video self-ratings tracked day-to-day score changes.
Get the monthly update by email
Subscribe here to receive an email when a new monthly spinocerebellar ataxia update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).